📢 Breaking News: Empowering the next wave of women entrepreneurs—HerSTART 5.0 is coming soon.

Babycue Private Limited

4

Babycue Private Limited tackles childhood diarrheal mortality and antimicrobial resistance (AMR) with its disposable, rapid PoC diagnostic kits. The affordable paper analytical test empowers point-of-care decision making in clinical and rural environments throughout SAARC countries.

Founders

Mr. Manish Kumar Swain | Dr. Itishree Jali | Ms. Sefali Maurya

Healthcare / MedTech Diagnostics

The Problem:

Childhood diarrhea remains a major public health challenge, with a global prevalence exceeding 63% and an estimated 525,000 deaths annually, despite the availability of simple and effective treatments. In developing countries, including India, children experience diarrhea on average three times per year, with a mortality rate of approximately 9–9.5%, resulting in nearly 300 deaths each day. Key contributing factors include poor sanitation, unsafe drinking water, child growth failure, and the rising burden of antibiotic resistance. In the absence of early point-of-care tools to accurately differentiate the etiology of diarrhea, doctors often give antibiotics unnecessarily, which further exacerbates antimicrobial resistance. This underscores the urgent need for innovative diagnostic solutions that enable early differentiation of diarrheal causes, thereby supporting evidence-based clinical decision-making and ensuring more targeted treatment.

The Solution:

We have developed a point-of-care lateral flow assay (LFA) based test-platform to detect the childhood diarrhea (≤5 years). Our device helps in early detection and differentiation of bacterial from non-bacterial diarrhea. based test-platform that can be an early diagnosis tool that will, potentially, help in differentiating childhood diarrhea (≤5 years) i.e., bacterial diarrhea from non-bacterial  diarrhea. It will improve clinical decision-making appropriateness, reduce childhood mortality and antimicrobial resistance (AMR), streamline resource allocation, and adverseness associated with injudicious medication usage.

Who Benefits?

  • Pediatric healthcare professionals and hospitals
  • Children under 5 and their families in India and SAARC regions
  • Government and diagnostic programs targeting AMR reduction
37

Key Achievements

  • Patent published for rapid diagnosis device (PCT/IB2023/052710)
  • Pilot Deployments & Early Traction: Received pilot orders (1300 kits from Chief Medical & Health Officer, Dantewada; 1500 kits from Mild Cares
  • Validation trials at major hospitals
  • We have received grants from BIRAC, NIDHI PRAYAS, SBI Foundation (C-CAMP), MSME Idea Hackathon 2.0, Startup Odisha MAG, Pfizer INDovation, and won the 1st Prize at COEP Bhau Institute’s Social Innovation Summit 2025
  • Global Bio-India Roadshow winner, C-CAMP AMR Innovator School participant

Societal Impact

BabyCue is creating a strong societal impact by addressing childhood diarrhea, a leading cause of child mortality, through its rapid, affordable, and non-invasive diagnostic platform. By enabling quick differentiation between bacterial and non-bacterial diarrhea, it ensures appropriate treatment while reducing unnecessary antibiotic use and combating antimicrobial resistance. Its accessible, eco-friendly, and cost-effective design makes it especially valuable in resource-limited settings, improving child health outcomes, lowering healthcare costs, and advancing global health equity.

Vision for the Future

Year 1: Distribution expansion in India, regulatory clearances

Year 2: Enter SAARC, scale up manufacturing

Year 3: Advanced tech upgrades, new diagnostics lines

Leave a Reply

Your email address will not be published. Required fields are marked *